Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Receives DSMB Approval To Advance Final Dose Level With PLX-PAD
Reportedly, Pluristem is expected to involve 15 adults in the study. The Phase I study is designed to evaluate the safety of PLX-PAD on three dose levels in
Reportedly, Pluristem is expected to involve 15 adults in the study. The Phase I study is designed to evaluate the safety of PLX-PAD on three dose levels in
The trial is expected to evaluate three HCV antiviral agents, including the investigational protease inhibitor ABT-450, part of the Abbott-Enanta collaboration and polymerase inhibitors ABT-333 and ABT-072 currently
As previously announced, in October 2009, Impax has reached agreement with Astellas Pharma and Boehringer Ingelheim Pharmaceuticals to settle US patent litigation related to its ANDA for its
It represents an important milestone for Immunovaccine as it further validates the potential of its vaccine platform, and enables the company to apply the upfront signing fees, and
As per the terms of the acquisition Hi-Tech will receive rights to Mag-Ox, Maginex, Uro-Mag and Corban. The brands will be sold through the company’s Health Care Products
Intercell has posted a net income of EUR7.5m, compared to EUR30.96m for the comparable period in 2008. For the full year ended December 31, 2009, the company has
Stirling said that the facility has been purchased on terms at a major discount to the going-concern replacement value (estimated by the company to be in excess of
The agreement provides Kyowa Hakko Kirin with an exclusive right to market and sell SP-01 (extended release transdermal granisetron patch; brand name: Sancuso) in Taiwan, Hong Kong, Singapore
Sanofi-aventis has secured exclusivity for the Unifill syringe within the full therapeutic classes of antithrombotic agents and vaccines until June 30, 2014 (period of exclusivity). The two therapeutic
NCX 116 has completed two phase 2 studies in patients with glaucoma and ocular hypertension that demonstrated promising results. As per the terms of the agreement, Bausch +